Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 30 | $106.82 | $3,204.60 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,838 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 70 | $106.81 | $7,476.70 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,868 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $106.78 | $21,356.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,938 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $106.78 | $21,355.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,138 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $106.77 | $21,354.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,338 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $106.76 | $32,028.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,538 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $106.76 | $10,675.50 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,838 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 900 | $106.71 | $96,039.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,938 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $106.70 | $42,680.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,838 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 800 | $106.69 | $85,352.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,238 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $106.68 | $10,667.50 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,038 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 70 | $106.67 | $7,466.90 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,138 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 30 | $106.66 | $3,199.80 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,208 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $106.65 | $10,664.50 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,238 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $106.64 | $10,664.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,338 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $106.56 | $21,312.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,438 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 20 | $106.56 | $2,131.10 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,638 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 80 | $106.50 | $8,520.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,658 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 190 | $106.50 | $20,234.05 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,738 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 110 | $106.49 | $11,713.90 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,928 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $106.46 | $21,292.00 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,038 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 20:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 25,124 | $73.70 | $1,851,638.80 |
DisclosureSEC source: 0001127602-18-009028 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 26, 2018 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 2,215 | $109.34 | $242,188.10 |
DisclosureSEC source: 0001127602-18-008368 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,390 Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 81,181 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-18-008368 · form4.xml · derivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,181 Underlying: Common Stock · 81,181 shares Expires 2023-02-23 F2 · derivative.exercise_date: Stock options vest as follows: 20,295 options vest one (1) year from the date of grant, 20,295 options vest two (2) years from the date of grant, 20,295 options vest (3) years from the date of grant, and 20,296 options vest four (4) years from the date of grant. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 17,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008368 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,605 F1 · security: Consists of 17,984 unvested restricted stock units that vest equally over four (4) years beginning one (1) year from the date of issuance. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 19:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 46 | $107.50 | $4,945.00 |
DisclosureSEC source: 0001127602-18-007066 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · 2017 GRAT Disclosed balance after: 29,954 F1 · balance_after: On 8/31/2017, the reporting person contributed 30,000 shares of CRL common stock to a grantor retained annuity trust for the benefit of himself and his 2 adult children. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 19:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 27,555 | $106.97 | $2,947,558.35 |
DisclosureSEC source: 0001127602-18-002632 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,829 Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 19:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 65,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-002632 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,384 F1 · kind: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 27, 2015. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $110.55 | $22,110.00 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,266 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $109.46 | $43,784.00 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,466 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $110.50 | $44,200.00 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,866 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $110.48 | $22,095.00 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,266 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.46 | $11,045.50 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,466 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 62 | $110.45 | $6,847.90 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,566 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 38 | $110.45 | $4,196.91 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,628 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $110.43 | $44,172.00 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,666 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $110.42 | $22,084.00 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,066 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 90 | $110.42 | $9,937.35 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,266 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.39 | $11,039.00 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,356 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.39 | $11,038.50 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,456 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 75 | $110.38 | $8,278.50 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,556 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $110.37 | $44,148.00 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,631 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.37 | $11,036.50 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,031 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:17 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 600 | $110.36 | $66,216.00 |
DisclosureSEC source: 0001127602-18-000936 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,131 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $110.35 | $33,105.00 |
DisclosureSEC source: 0001127602-18-000934 · form4.xml · nonDerivative · entry 26 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,731 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $110.34 | $44,136.00 |
DisclosureSEC source: 0001127602-18-000934 · form4.xml · nonDerivative · entry 25 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,031 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $110.32 | $22,064.00 |
DisclosureSEC source: 0001127602-18-000934 · form4.xml · nonDerivative · entry 24 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,431 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $110.31 | $11,031.00 |
DisclosureSEC source: 0001127602-18-000934 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,631 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 490 | $110.30 | $54,047.00 |
DisclosureSEC source: 0001127602-18-000934 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,731 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 90 | $110.26 | $9,923.40 |
DisclosureSEC source: 0001127602-18-000934 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,221 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.